Clinical Trial

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

Study acronym: REBEL
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-05
notable Primary completion pushed: 2030-05 -> 2030-06 2026-06-05
minor Completion pushed: 2031-05 -> 2031-06 2026-06-05
Trial Details
NCT Number NCT07528352
Lead Sponsor University of Utah
Conditions Diffuse Large B Cell Lymphoma
Enrollment 12 participants
Start Date 2026-06-01
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-04